Return to Exhibit Hall »
At Myriad Genetics, our goal is to make a difference in patients’ lives and is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. We are expanding our reach and increasing our impact on patient care by introducing new molecular diagnostic and companion diagnostic tests for a growing number of diseases. The following NCCN and ASCO-approved germline and tumor testing options are available:
Germline tests:
- myRisk® determines secondary and familial risk of hereditary cancers.
- BRACAnalysisCDx® identifies patients with breast, ovarian, pancreatic, or prostate cancer that will preferentially benefit from PARPi therapy.
Tumor tests:
- EndoPredict® assesses a patient’s risk of breast cancer recurrence out to 15 years.
- myChoiceCDx® determines the HRD status in patients with ovarian cancer, determining who is eligible for approved targeted PARPi therapy.
- Prolaris® provides a personalized risk assessment of your patient’s prostate cancer and tumor aggressiveness.
- myPath® measures the genes for which expression patterns differ between malignant melanoma and benign nevi.
For more detailed information, please visit:
https://myriad-oncology.com/providers/
Contact:
Lina Walther
E-mail - lwalther@myriad.com
